Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease

IntroductionBlepharospasm is uncommon in Parkinson's disease, especially in the peak-dose dyskinesia period. Case presentationWe herein present the case of a patient with PD who developed blepharospasm in the peak-dose dyskinesia period. The symptom was improved by taking amantadine. ConclusionThe current report expands the phenomenology of peak-dose dykinesia in PD to include dystonic blepharospasm. This complication of levodopa therapy may respond to amantadine despite the dystonic appearance of movements.